Preoperative peripheral naïve/memory ratio and prognosis of nonsmall-cell lung cancer patients

Annals of Thoracic and Cardiovascular Surgery

Volumn 13, Issue 6, 2007, Pages 384-390

  Hara, Masaki ^a   Matsuzaki, Yasunori ^a   Shimizu, Tetsuya ^a   Tomita, Masaki ^a   Ayabe, Takanori ^a   Enomoto, Yusuke ^a   Onitsuka, Toshio ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

CD4; CD45RA; CD45RO; Nonsmall cell lung cancer; Prognosis

Indexed keywords

CD45 ANTIGEN;

AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; FEMALE; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL;

AGED; ANTIGENS, CD45; CARCINOMA, NON-SMALL-CELL LUNG; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 40949111477     PISSN: 13411098     EISSN: 21861005     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Boon T, Cerottini JC, Van den Eynde B, et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12: 337-65.
2. + T cells in antitumor immunity. Trends Immunol 2001; 22: 269-76.
3. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10: 281-7.
4. + T cells. J Exp Med 1999; 189: 757-66.
5. Wang RF, Wang X, Atwood AC, et al. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999; 284: 1351-4.
6. Schoenberger SP, Toes RE, van der Voort EI, et al. Tcell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480-3.
7. + T helper and a T-killer cell. Nature 1998; 393: 474-8.
8. Bennett SR, Carbone FR, Karamalis F, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-80.
9. Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 2003; 21: 107-37.
10. Penninger JM, Irie-Sasaki J, Sasaki T, et al. CD45: new jobs for an old acquaintance. Nat Immunol 2001; 2: 389-96.
11. Trowbridge IS, Thomas ML. CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol 1994; 12: 85-116.
12. Tchilian EZ, Beverley PC. Altered CD45 expression and disease. Trends Immunol 2006, 27: 146-53.
13. Akbar AN, Terry L, Timms A, et al. Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells. J Immunol 1988; 140: 2171-8.
14. Tosi P, Sforza V, Santopietro R, et al. Bronchiolo-alveolar carcinoma: an analysis of survival predictors. Eur J Cancer 1992; 28A: 1365-70.
15. Takenoyama M, Yasumoto K, Harada M, et al. Expression of activation-related molecules on regional lymph node lymphocytes in human lung cancer. Immunobiology 1996; 195: 140-51.
16. De Paoli P, Battistin S, Santini GF. Age-related changes in human lymphocyte subsets: progressive reduction of the CD4 CD45R (suppressor inducer) population. Clin Immunol Immunopathol 1988; 48: 290-6.
17. Hannet I, Erkeller-Yuksel F, Lydyard P, et al. Developmental and maturational changes in human blood lymphocyte subpopulations. Immunol Today 1992; 13: 215-8.
18. +) T-helper cells after human allogeneic bone marrow transplantation. Blood 1997; 90: 850-7.
19. Kuss I, Schaefer C, Godfrey TE, et al. Recent thymic emigrants and subsets of naïve and memory T cells in the circulation of patients with head and neck cancer. Clin Immunol 2005; 116: 27-36.
20. Thude H, Hundrieser J, Wonigeit K, et al. A point mutation in the human CD45 gene associated with defective splicing of exon A. Eur J Immunol 1995; 25: 2101-6.
21. Stanton T, Boxall S, Hirai K, et al. A high-frequency polymorphism in exon 6 of the CD45 tyrosine phosphatase gene (PTPRC) resulting in altered isoform expression. Proc Natl Acad Sci USA 2003; 100: 5997-6002.
22. Gomez-Lira M, Liguori M, Magnani C, et al. CD45 and multiple sclerosis: the exon 4 C77G polymorphism (additional studies and meta-analysis) and new markers. J Neuroimmunol 2003; 140: 216-21.
23. Boxall S, Stanton T, Hirai K, et al. Disease associations and altered immune function in CD45 138G variant carriers. Hum Mol Genet 2004; 13: 2377-84.
24. Khaled AR, Durum SK. Death and Baxes: mechanisms of lymphotrophic cytokines. Immunol Rev 2003; 193: 48-57.
25. + T cell responses to influenza vaccine. J Immunol 2004; 173: 673-81.
26. Ishikawa H, Mahmoud MS, Fujii R, et al. Proliferation of immature myeloma cells by interleukin-6 is associated with CD45 expression in human multiple myeloma. Leuk Lymphoma 2000; 39: 51-5.
27. Foss FM. Immunologic mechanisms of antitumor activity. Semin Oncol 2002; 29: 5-11.
28. - subpopulations. J Immunol 2000; 165: 3105-10.
29. high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245-53.
30. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 2756-61.
31. Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002; 100: 2132-7.
32. + T cells with regulatory properties from human blood. J Exp Med 2001; 193: 1303-10.
33. + regulatory cells that control intestinal inflammation. J Exp Med 2000; 192: 295-302.
34. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192: 303-10.
35. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-6.
36. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100: 8372-7.
37. +T cells in peripheral blood and pleural effusion from lung adenocarcinoma patients. Lung Cancer 2005; 47: 361-71.